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Abstract
Introduction: Haemoglobin A1c (HbA1c) is widely used in the management of diabetes. Therefore, the reliability and comparability among different 
analytical methods for its detection have become very important. 
Materials and methods: A comparative evaluation of the analytical performances (precision, linearity, accuracy, method comparison, and interfe-
rences including bilirubin, triglyceride, cholesterol, labile HbA1c (LA1c), vitamin C, aspirin, fetal haemoglobin (HbF), and haemoglobin E (Hb E)) were 
performed on Capillarys 2 Flex Piercing (Capillarys 2FP) (Sebia, France), Tosoh HLC-723 G8 (Tosoh G8) (Tosoh, Japan), Premier Hb9210 (Trinity Biotech, 
Ireland) and Roche Cobas c501 (Roche c501) (Roche Diagnostics, Germany).
Results: A good precision was shown at both low and high HbA1c levels on all four systems, with all individual CVs below 2% (IFCC units) or 1.5% 
(NGSP units). Linearity analysis for each analyzer had achieved a good correlation coefficient (R2 > 0.99) over the entire range tested. The analytical 
bias of the four systems against the IFCC targets was less than ± 6% (NGSP units), indicating a good accuracy. Method comparison showed a great 
correlation and agreement between methods. Very high levels of triglycerides and cholesterol (≥ 15.28 and ≥ 8.72 mmol/L, respectively) led to 
falsely low HbA1c concentrations on Roche c501. Elevated HbF induced false HbA1c detection on Capillarys 2FP (> 10%), Tosoh G8 (> 30%), Premier 
Hb9210 (> 15%), and Roche c501 (> 5%). On Tosoh G8, HbE induced an extra peak on chromatogram, and significantly lower results were reported. 
Conclusions: The four HbA1c methods commonly used with commercial analyzers showed a good reliability and comparability, although some in-
terference may falsely alter the result. 
Keywords: Haemoglobin A1c; capillary electrophoresis (CE); high-performance liquid chromatography (HPLC); affinity chromatography; immunoa-
ssay 
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Introduction
Haemoglobin A1c (HbA1c), a major portion of the 
glycated haemoglobins, is formed by a nonenzy-
matic interaction of glucose with the N-terminal 
valine residue of the HbA β chain in two basic 
steps: first, glucose binds reversibly to haemoglo-
bin (Hb) as an aldimine Schiff base (an intermedi-
ate, termed labile HbA1c (LA1c), or Hb pre-A1c); and 
then, the aldimine is transformed via an Amadori 
rearrangement into an irreversible ketoamine (1). 
Because HbA1c reflects a mean blood glucose level 
over 2–3 months (normal lifespan of red blood 
cells) with a low short-term variability, it is widely 
used in the management of diabetes to monitor 
long-term glycemic control and to assess the risk 
of developing complications (2,3). In the last sev-
eral years, the American Diabetes Association 
(ADA) and other major organizations have en-
dorsed the use of HbA1c determination for diabe-
tes screening and have suggested the value of 
6.5% (48 mmol/mol) as a diagnostic cut-off (4,5). 
Analytical methods for HbA1c quantification have 
been available since the 1970s. Presently, a num-
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ber of methods are used: the capillary electropho-
resis (CE) or ion-exchange chromatography meth-
od separates and determines HbA1c from other Hb 
fractions based on charge differences; the boro-
nate affinity chromatography method separates 
and quantifies glycated Hb from the nonglycated 
Hb based on the cis-diol group; and the immuno-
assay method uses antibodies to recognize the 
structure of the N-terminal glycated amino acids 
of the Hb β chain for quantification (6). As different 
methods for HbA1c determination exhibit different 
characteristics and performances, over the past 
years, major efforts have been made by the Na-
tional Glycohemoglobin Standardization Program 
(NGSP) and the International Federation of Clinical 
Chemistry and Laboratory Medicine (IFCC) to 
standardize HbA1c determination. The IFCC refer-
ence system has been defined as the only valid an-
chor to implement a standardization of the meas-
urement (7). However, variability between meth-
ods is still observed in the presence of other mem-
bers of the haemoglobin family (e.g., LA1c, fetal 
haemoglobin (HbF), and variants) or interfering 
substances in the samples (e.g., bilirubin, triglycer-
ide, cholesterol, and drugs) (8-13).
Due to clinical requirements and management de-
mands, the reliability of different methods used to 
measure HbA1c and their potential interchange 
ability represent a key feature in clinical practice. 
Therefore, the aim of this study was to evaluate 
the performances (precision, linearity, and accura-
cy), concordance (method comparison), and influ-
ence of the most frequent analytical interferences 
(bilirubin, triglyceride, cholesterol, LA1c, vitamin C, 
aspirin, HbF, and haemoglobin E (HbE)) using the 
four systems. The results of this study will be help-
ful for laboratorians to be aware of the limitations 
of the methods and to select the appropriate one 
that is less likely to have interference. 
Materials and methods
Analyzers 
Four systems were used to obtain HbA1c measure-
ments: a Capillarys 2 Flex Piercing (Capillarys 2FP) 
(Sebia, France) CE system, a Tosoh HLC-723 G8 (To-
soh G8) (Tosoh, Japan) (variant-mode) ion-ex-
change high-performance liquid chromatography 
(HPLC) system, a Premier Hb9210 (Trinity Biotech, 
Ireland) boronate affinity HPLC system, and a tur-
bidimetric inhibition immunoassay (TINIA) system 
using the Tina-quant Gen2 assay on a Roche Co-
bas c501 (Roche c501) (Roche Diagnostics, Germa-
ny) instrument. All four systems were certified by 
the IFCC and NGSP.
The analyzers as well as the associated reagents 
used for this evaluation were used according to 
the manufacturers’ instructions and calibrated 
only once according to their routine standard op-
erating procedures prior to any sample analysis. 
Internal quality controls (both low and high levels) 
supplied by the manufacturers and purchased 
from Bio-Rad Laboratories, Hercules, CA, USA (740 
Diabetes Controls, lot: 33861/33862) were meas-
ured along with the samples on the same day dur-
ing this study. The same assessment test by the 
four systems was carried out on the same day by 
the same technician in our laboratory. The same 
assessment test by one system was carried out us-
ing the same batch accompanied with the same 
controls. 
Samples
Whole blood samples (N = 157) and umbilical cord 
blood (N = 1) were collected in EDTA-containing 
tubes (2.0 mL, BD Diagnostics, Franklin Lakes, NJ, 
USA) and kept at 4 ± 2 ºC to be analyzed within 24 
h. For precision, method comparison, and analyti-
cal interference of Hb variants, the samples were 
kept at - 80 °C (14,15) and analyzed within 1 month. 
Whole blood samples were obtained from the 
Clinical Laboratory of Guangdong Provincial Hos-
pital of Chinese Medicine. Umbilical cord blood 
was collected by clinicians at the Department of 
Obstetrics and Gynecology of the Third Affiliated 
Hospital, Guangzhou Medical University, from the 
umbilical cord vein attached to the placenta, 
which had been detached from a newborn. Whole 
blood samples (N = 151) were collected according 
to HbA1c concentrations (3.0–15.0%; 9–140 mmol/
mol) on a Premier Hb9210 instrument, with HbF < 
1%, normal HbA2 (2.5–3.5%), and without Hb vari-
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ants on the Hb phenotype analysis by Bio-Rad Var-
iant II (Bio-Rad, Japan) system using the beta 
thalassemia program. The Hb variants HbA/E (N = 
6) (a substitution of lysine for glutamic acid at posi-
tion 26 of the β chain) were collected from routine 
laboratory testing samples for thalassemia and 
confirmed by DNA sequencing of Hb α and 
β-chain gene (HBA1, HBA2 and HBB) at the Beijing 
Genomics Institute (BGI, Shenzhen, China). 
This study was approved by the Research and Eth-
ics committee of our institution, and all partici-
pants signed their consents prior to the study. 
Precision 
The precision was evaluated in accordance with 
the EP15-A2 (16) protocol of the Clinical and Labo-
ratory Standards Institute (CLSI). Two whole blood 
samples at levels of 5.0% (31 mmol/mol) and 8.5% 
(69 mmol/mol) by Premier Hb9210 were divided 
into five aliquots per level and frozen at -80 ºC. 
One aliquot of each level was thawed daily, and 
the HbA1c value was analyzed three times per day 
during a period of five consecutive workdays (N = 
15 per level). Precision was evaluated as the coeffi-
cient of variation (CV), which is calculated from the 
data series mean and standard deviation. The for-








































%CVwithin = Swithin/ X × 100%  (4)
%CVtotal = Stotal/ X × 100%   (5)
where D is the total number of days (five), n is the 
total number of replicates per day (three), Xdi is the 
result of replicate i for day d, dX  is the average of 
all results for day d, and X is the average of all re-
sults. 
Acceptable CV is recommended to be less than 3% 
for SI units and 2% for NGSP units (17-19).
Linearity 
A test for linearity was carried out in accordance 
with the CLSI protocol EP6-A 8 (20). Linearity was 
investigated by preparing six different ratios of 
samples (5:0, 4:1, 3:2, 2:3, 1:4, and 0:5) from two 
samples with HbA1c results of 4.2% (22 mmol/mol) 
and 14.9% (139 mmol/mol) by Premier Hb9210 
containing the same total Hb concentration (129 
g/L). Each sample was assayed in duplicate, and 
the means were used to examine the linearity. The 
theoretical HbA1c values (calculated from the ratios 
of the mixed packed-cells with high and low HbA1c 
values) and the measured values were compared. 
Polynomial regression analysis was performed for 
first-, second-, and third-order polynomials.
Accuracy
Four samples used in the method comparison 
were validated by the Shanghai IFCC Reference 
Laboratory using the IFCC HPLC/CE reference 
method (21). The measurements of HbA1c were 
made in triplicate. The relative bias was calculated 
by each of the four system values against the IFCC 
reference method value for each sample. The pro-
ficiency testing acceptance limit ± 6% of College 
of American Pathologists (CAP) was set as the ac-
curacy limit (relative bias was calculated by NGSP 
units) (7).
Method comparison 
The correlation between systems was assessed by 
analyzing 93 samples representing a range of 
HbA1c values 4.0–13.0% (20–119 mmol/mol) by Pre-
mier Hb9210. The boronate affinity HPLC method 
with the Premier Hb9210 instrument was used as 
the comparative method.
x
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Analytical interferences 
Bilirubin, triglycerides/cholesterol, LA1c, vitamin C, 
and aspirin
Interferences of bilirubin, triglycerides/cholesterol, 
LA1c, vitamin C, and aspirin were evaluated in two 
native samples with HbA1c results of 5.3% (34 
mmol/mol) and 7.6% (60 mmol/mol) by Premier 
Hb9210. Hyperbilirubinemic or triglycerides/cho-
lesterol-rich plasma and drugs (glucose, vitamin C, 
and aspirin) were prepared: bilirubin (< 10 μmol/L 
and 445.50 μmol/L; measured by Roche Modular P 
Chemistry Analyzer (Modular P), Roche Diagnos-
tics, Germany), triglyceride (1.48, 10.21, and 19.10 
mmol/L; measured by Roche Modular P), choles-
terol (4.63, 10.29, and 10.90 mmol/L; measured by 
Roche Modular P), glucose (277.78 mmol/L; China 
Otsuka Pharmaceutical, Tianjin, China), vitamin C 
(ascorbic acid; 250 mg/mL; CSPC Ouyi Pharmaceu-
tical, Shijianzhuang, China), and aspirin (100 mg; 
Bayer Healthcare, Milano, Italy). Then, various dilu-
tions were prepared by mixing the original pool 
with plasma or isotonic saline solution (0.9%, Ji-
angxi pharmaceutical, Ganzhou, China).
Interferences of bilirubin and triglycerides/choles-
terol were assessed by mixing washed red blood 
cells with various dilutions of hyperbilirubinemic 
or triglycerides/cholesterol-rich plasma to achieve 
final concentrations of 89.10, 178.20, 267.30, 356.40, 
and 445.50 μmol/L bilirubin; 2.04, 4.08, 6.12, 8.16, 
and 10.21 mmol/L triglycerides; 2.06, 4.12, 6.18, 
8.23, and 10.29 mmol/L cholesterol; and 3.82 / 2.18, 
7.64 / 4.36, 11.46 / 6.54, 15.28 / 8.72, and 19.10 / 
10.90 mmol/L triglycerides/cholesterol.
Interference of LA1c was examined by incubating 
samples with various dilutions of glucose solutions 
(5.65, 27.78, 55.56, 138.89, and 277.78 mmol/L) at 37 
°C for 3 h, and the samples were mixed every 30 
min prior to the assay (22). The amount of LA1c 
formed was estimated using a Tosoh G8 analyzer 
(LA1c can be separated from HbA1c and others, and 
the percentage value is the percentage of total Hb 
as reported). 
Interference of vitamin C or aspirin was performed 
by mixing blood samples spiked with various dilu-
tions of vitamin C or aspirin solution (final concen-
trations: 25, 50, 100, 150, 200, and 250 mg/mL vita-
min C; and 6.66, 13.32, 19.98, 26.64, and 33.30 mg/
mL aspirin). 
The measurements of HbA1c were made in tripli-
cate, and the relative bias of each specimen was 
calculated from the observed value against the 
baseline value.
HbF
Interference with HbF was evaluated by mixing 40 
native samples representing a range of HbA1c val-
ues (4–13%; 20–119 mmol/mol) with umbilical cord 
blood in order to obtain 6 groups with final HbF 
concentrations of 5–10% (N = 5), 10–15% (N = 5), 
15–20% (N = 7), 20–25% (N = 10), 25–30% (N = 5), 
and 30–40% (N = 8). The HbF concentration was 
analyzed by the Tosoh G8 instrument as the HbF 
percentage (HbF can be separated from HbA1c and 
others, and the percentage value is the percent-
age of total Hb as reported). 
The measurements of HbA1c were made in tripli-
cate. The relative bias of each specimen was calcu-
lated from the observed value and the baseline 
value (NGSP units). 
Hb variant
Interference with a Hb variant was tested in sever-
al samples containing the most frequent Hb vari-
ant HbA/E (N = 6). The boronate affinity HPLC 
method with the Premier Hb9210 instrument was 
used as the comparative method as it is not ex-
pected to be influenced by the presence of Hb 
variants (23). For each test method, the results 
were compared to those obtained using the com-
parison method. 
Statistical analysis
Data analysis was performed using MedCalc ver-
sion 14.8.1 (MedCalc Software, Ostend, Belgium). 
The method comparisons were performed by 
Passing-Bablok regression, and the differences be-
tween any two methods were presented in a 
Bland-Altman plot. For method comparison and 
analytical interferences, relative bias > ± 7% (cal-
culated by NGSP units) was considered clinically 
significant (NGSP criterion) (7).
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Results
Precision 
The within-run CVs at low and high HbA1c concen-
trations on all four systems were less than 2.0% 
and 1.2% (with IFCC units), or 1.3% and 1.0% (with 
NGSP units), respectively (Table 1). The total CVs at 
the low and high HbA1c levels were less than 2.0% 
and 1.7% (with IFCC units), and 1.4% and 1.5% 
(with NGSP units), respectively (Table 1).
Linearity 
The linear regression analysis for each of the four 
analyzers showed a line with a good correlation 
coefficient (R2 > 0.99) over the entire range tested 
(Table 1).
Accuracy
The relative bias against the IFCC targets was less 
than ± 6% for all four systems tested (NGSP units), 
indicating a good accuracy of these methods (Ta-
ble 2).
Method comparison
The correlation between the Capillarys 2FP and 
Premier Hb9210 analyzers, expressed in NGSP 
units, is described with the Passing-Bablok regres-
sion fit: Y = 1.07 (95% confidence interval (CI): 1.03 
to 1.10) X – 0.31 (95% CI: - 0.51 to - 0.08), without 
significant deviation from linearity (P = 0.13) (Fig-
ure 1A). The Bland-Altman plot showed a mean 
absolute difference of 0.13% HbA1c (Figure 1B). All 
samples had less than 7% relative difference.
The correlation between the Tosoh G8 and Pre-
mier Hb9210 analyzers, expressed in NGSP units, is 
described with the Passing-Bablok regression fit: Y 
= 1.02 (95% CI: 1.00 to 1.05) X – 0.01 (95% CI: - 0.23 
to 0.10), without significant deviation from lineari-
ty (P = 0.46) (Figure 1C). The Bland-Altman plot 
showed a mean absolute difference of 0.13% HbA1c 
(Figure 1D). All samples had less than 7% relative 
difference.
The correlation between the Roche c501 and Pre-
mier Hb9210 analyzers, expressed in NGSP units, is 
described with the Passing-Bablok regression fit: Y 






















































































































































































































































































































































































































































































































Table 1. Precision and linearity of HbA1c values analyzed by the 
four analyzers
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Sample 
number 













1 5.4 5.4 5.7 5.2 5.2 0.0 5.6 -3.7 -3.7
2 6.1 6.4 6.2 6.0 6.2 4.9 1.6 -1.6 1.6
3 7.8 7.9 8.0 7.6 7.6 1.3 2.6 -2.6 -2.6
4 10.4 10.7 10.5 10.3 10.1 2.9 1.0 -1.0 -2.9
The CAP proficiency testing acceptance limit of ± 6% was set as the accuracy limit (relative bias was calculated by NGSP units).
Table 2. Accuracy of HbA1c values analyzed by the four analyzers
to 0.45), without significant deviation from lineari-
ty (P = 0.08) (Figure 1E). The Bland-Altman plot 
showed a mean absolute difference of -0.04% 
HbA1c (Figure 1F). All samples had less than 7% rel-
ative difference.
Analytical interferences 
Assessment of interferences is shown in Table 3. 
No interference was observed with Capillarys 2FP, 
Premier Hb9210, and Tosoh G8 at the following in-
terfering substance concentrations tested: 445.50 
μmol/L bilirubin, 10.21 mmol/L triglyceride, 10.29 
mmol/L cholesterol, or 19.10 / 11.90 mmol/L tri-
glycerides/cholesterol. On Roche c501 analyzer, no 
analytical interference of bilirubin was noticed for 
concentrations reaching 445.50 μmol/L; while, at 
concentrations of 15.28 / 8.72 and 19.10 / 11.90 
mmol/L triglycerides/cholesterol, a significant bias 
was observed (relative bias > ± 7%). 
A glucose concentration less than 277.78 mmol/L 
(LA1c < 10.9%) did not interfere with HbA1c quanti-
fication on any of the four analyzers. In addition, 
no significant bias was observed with the results 
analyzed by the Capillarys 2FP analyzer in the 
presence of vitamin C up to 250 mg/mL. In con-
trast, using the Premier Hb9210 and Tosoh G8 ana-
lyzers, vitamin C concentrations of more than 50 
and 150 mg/mL, respectively, interfered with the 
HbA1c measurements. 
Moreover, the HbA1c value was falsely increased 
only with the Tosoh G8 analyzer at an aspirin con-
centration exceeding 26.64 mg/mL in the samples.
Compared with the native sample, on the Capillar-
ys 2FP analyzer, significant biases were observed 
in samples with 10–15% HbF (relative bias > ± 7%). 
On the Premier Hb9210 analyzer, the results were 
not affected in the two groups of samples with 5 
–10% and 10–15% HbF (relative bias < ± 7%). On 
the Tosoh G8 analyzer, the HbA1c results were ob-
tained by a correction via excluding the HbF peak 
from the total integrated area, resulting in an in-
significant interference in the samples with HbF < 
30% (relative bias < ± 7%). For all samples analyzed 
by the Roche c501 analyzer, the HbA1c results were 
influenced by elevated HbF values > 5% (relative 
bias > ± 7% for all groups). 
The Capillarys 2FP analyzer gave a perfect separa-
tion of the variant HbE; on the Tosoh G8 analyzer, 
an extra peak was present between the A1c and A0 
peaks (Figure 2). A rather good agreement was no-
ticed between the Capillarys 2FP/Roche c501 and 
Premier Hb9210 analyzers (relative bias < ± 7%); 
meanwhile, a significant negative bias of HbA1c 
values was observed systematically on the Tosoh 
G8 system in comparison with the Premier Hb9210 
analyzer (relative bias > ± 7%). 
Discussion 
The data presented here are comparative evalua-
tions of the analytical performance of four com-
monly used systems: Capillarys 2FP, Tosoh G8, Pre-
mier Hb9210, and Roche c501 Tina-quant Gen2. 
Precision studies showed good performances, 
with CVs of the four HbA1c assays well within the 
recommendations (below 3% for IFCC units and 
2% for NGSP units) (17-19). The linearity was excel-
lent over the clinical range of HbA1c values. Accu-
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Figure 1. Comparison of HbA1c values obtained with four analyzer using Passing and Bablok (PB) regression analysis and Bland-Alt-
man (BA) plot. (A) Comparison of Capillarys 2FP and Premier Hb9210 by PB. (B) Comparison of Capillarys 2FP and Premier Hb9210 by 
BA. (C) Comparison of Tosoh G8 and Premier Hb9210 by PB. (D) Comparison of Tosoh G8 and Premier Hb9210 by BA. (E) Comparison 
of Roche c501 and Premier Hb9210 by PB. (F) Comparison of Roche c501 and Premier Hb9210 by BA. In the Passing-Bablok regression 
analyses the dotted lines show the 95% confidence interval (CI); the gray lines represent the identity line (X = Y). In the Bland-Altman 
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Interferent
Relative bias from native sample, %
Capillarys 2 FP TOSOH G8 Premier Hb9210 Roche c501
Low High Low High Low High Low High
TBIL, µmol/L
89 .1 3.64 0.00 1.89 0.00 1.89 - 2.63 1.13 0.26
178 .2 - 1.82 0.00 0.00 1.28 1.89 - 1.32 1.89 - 0.79
267 .3 - 3.64 3.85 0.00 0.00 1.89 0.00 1.32 - 1.18
356 .4 - 1.82 1.28 1.89 0.00 1.89 - 1.32 - 0.19 - 2.76
445 .5 - 1.82 1.28 1.89 0.00 1.89 1.32 - 0.38 - 3.55
TG, mmol/L
2 .04 - 3.64 1.28 1.89 0.00 0.00 - 1.32 - 1.13 3.42
4 .08 - 3.64 2.56 0.00 0.00 0.00 - 2.63 - 2.45 1.32
6 .12 - 3.64 1.28 0.00 - 1.28 - 1.89 - 2.63 - 1.51 - 1.45
8 .16 - 3.64 - 1.28 0.00 - 1.28 - 1.89 - 3.95 - 3.77 1.18
10 .21 - 1.82 - 1.28 0.00 0.00 1.89 - 1.32 - 0.38 - 1.71
CHOL, mmol/L
2 .06 - 3.64 - 2.56 0.00 0.00 1.89 - 1.32 - 2.83 - 3.68
4 .12 - 3.64 - 3.85 1.89 0.00 0.00 - 1.32 - 2.83 - 3.16
6 .18 - 3.64 - 1.28 0.00 - 1.28 1.89 - 1.32 - 4.53 - 3.16
8 .23 - 3.64 - 3.85 0.00 - 1.28 1.89 - 1.32 - 4.15 - 1.58
10 .29 0.00 - 1.28 - 1.89 - 1.28 0.00 - 1.32 - 3.21 - 2.50
TG/CHOL, mmol/L
3 .82 / 2 .18 - 3.64 - 1.28 1.89 0.00 3.77 - 1.32 - 1.70 - 3.55
7 .64 / 4 .36 0.00 - 1.28 0.00 1.28 1.89 - 2.63 - 2.83 - 3.42
11 .46 / 6 .54 0.00 0.00 1.89 - 1.28 1.89 - 1.32 - 4.15 - 3.42
15 .28 / 8 .72 0.00 2.56 1.89 0.00 3.77 - 2.63 - 7 .74 - 5.13
19 .10 / 11 .90 0.00 1.28 1.89 0.00 3.77 - 2.63 - 8 .79 - 5.26
Vit C, mg/mL
25 / / / / 3.8 4.8 / /
50 1.92 0.00 3.70 1.23 20 .75 10 .53 4.53 -1.45
100 0.00 - 1.27 5.56 1.23 50 .94 25 .00 6.42 6.32
150 - 5.77 1.27 14 .81 4.94 56.60 32.89 10.00 7.37
200 1.92 - 2.53 24 .07 7 .41 52 .83 34 .21 6.04 5.92
250 0.00 0.00 22 .22 8 .64 50 .94 32 .89 4.72 3.42
Aspirin (mg/mL)
6 .66 - 1.82 - 2.56 3.70 0.00 1.89 - 1.32 3.58 - 0.53
13 .32 - 1.82 - 3.85 5.56 1.23 3.77 - 1.32 2.08 1.18
19 .98 - 3.64 - 5.13 5.56 2.47 1.89 - 1.32 2.08 - 1.18
26 .64 - 3.64 0.00 9 .26 2.47 1.89 0.00 - 0.19 0.13
33 .33 - 3.64 - 1.28 11 .11 3.70 0.00 - 2.63 2.45 1.45
Glu (mmol/L)
5 .56 1.82 1.16 0.00 0.00 0.00 1.19 2.82 4.81
27 .78 - 1.82 1.16 0.00 0.00 0.00 0.00 - 0.56 4.44
55 .56 - 3.64 0.00 0.00 - 3.49 1.82 - 2.38 0.00 0.99
138 .89 - 3.64 - 1.16 0.00 - 3.49 1.82 - 2.38 1.13 0.74
277 .78 - 3.64 0.00 0.00 - 4.65 5.45 - 1.19 2.07 0.00
Low - whole blood sample with HbA1c concentration of 5.3% measured by Premier Hb9210. High - whole blood sample with HbA1c 
concentration of 7.6% measured by Premier Hb9210. TBIL - total bilirubin. TG – triglycerides. CHOL – cholesterol. Vit C - vitamin C. 
Glu - glucose. “/” - not performed. The bold results show relative bias > ± 7% (calculated by NGSP units). Relative bias > ± 7% was 
considered clinically significant (NGSP criterion).
Table 3. Sample interferences for common interferents
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racy verification demonstrated a great consistency 
among the four systems tested in comparison 
with the IFCC values. The high analytical perfor-
mances in terms of precision, linearity, and accura-
cy of all four systems were in accordance with pre-
vious studies (15,24-27) and manufacturer claims.
In the HbA1c comparison study, Passing-Bablock 
regression analysis highlighted a good correlation 
between any two methods. Moreover, the Bland-
Altman plot showed that the HbA1c values be-
tween any two of the four systems were in good 
agreement. 
The measurement of HbA1c by the Capillarys 2FP, 
Tosoh G8, and Premier Hb9210 analyzers was not 
subjected to common interferences such as biliru-
bin and triglycerides/cholesterol, and these find-
ings confirmed the results presented previously 
(15,24,25,28). However, very high levels of triglycer-
ides/cholesterol led to a falsely low HbA1c value in 
the immunoassay using the Roche c501 system. 
Furthermore, it seems that samples with a low 
HbA1c value are more susceptible to interference. 
According to the manufacturer’s claim, no interfer-
ence is observed with lipemic samples containing 
triglycerides concentrations less than 15.52 
mmol/L. 
LA1c is an intermediate molecule, and its concen-
tration is associated with blood glucose concentra-
Sample
HbA1c, % Relative bias from Premier Hb9210, %
Premier Hb9210 Capillarys 2FP Tosoh G8 Roche c501 Capillarys 2FP Tosoh G8 Roche c501
1 5.5 5.6 4.2 5.4 1.8 -23 .6 -1.8
2 5.0 4.8 4.2 5.0 -4.0 -16 .0 0.0
3 5.3 5.3 4.7 5.6 0.0 -11 .3 5.6
4 5.1 5.2 4.1 5.2 2.0 -19 .6 2.0
5 5.6 5.9 4.6 5.7 5.4 -18 .0 1.8
6 5.6 5.3 4.6 5.4 -5.4 -18 .0 -3.6
The boronate affinity HPLC method with the Premier Hb9210 instrument was used as the comparative method. The bold results 
show the relative bias > ± 7% (calculated by NGSP units). Relative bias > ± 7% was considered clinically significant (NGSP criterion).
Table 4. HbA1c values for HbE on the Capillarys 2FP, Tosoh G8, Premier Hb9210, and Roche c501 systems
Figure 2. Detection of HbE with the Capillarys 2FP and Tosoh G8 analyzers. The arrow indicates the presence of the variant (HbE).
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tions. The isoelectric points of LA1c and its stable 
counterpart are similar, which may lead to little or 
no separation between them by some methods 
that rely on molecular charge for separation. In 
this study, no effect was reported on the quantifi-
cation of HbA1c by the two methods based on the 
principle of molecular charge. The current study 
showed that treatment with glucose up to 277.78 
mmol/L in vitro, much higher than the concentra-
tion reported previously (15,24,29) and the manu-
facturer’s claims, did not interfere with the HbA1c 
measurement, suggesting that the blood LA1c con-
tents may not affect the quantification of HbA1c by 
the four tested methods.
In our study, for the concentration of vitamin C or 
aspirin at a dose higher than clinical relevance, it is 
presumed that the concentration of vitamin C or 
aspirin in patient samples does not affect HbA1c re-
sults tested by the four analyzers in clinical prac-
tice. Chronic ingestion of aspirin or vitamin C in 
high doses may promote acetylation of HbA1c 
chains or inhibit Hb glycation, thereby affecting 
HbA1c results (13,30-33). Thus, the effects of aspirin 
and vitamin C on HbA1c assays are uncertain, and 
they may be of a biological nature rather than an 
analytical interference, although this needs to be 
investigated in a future study.
With the Capillarys 2FP instrument, at an increased 
proportion of HbF greater than 10%, which is in 
excess of that reported by Jaisson et al. (24), the 
separation of HbF and HbA0 could not be accom-
plished, resulting in a false result. As the HbF 
amount was excluded from the total integrated 
amount through using the Tosoh G8 instrument 
software, it may not interfere with the HbA1c meas-
urement at a concentration < 30%, in agreement 
with a previous evaluation and NGSP reports (7,8). 
Elevated HbF > 15%, in agreement with boronate 
affinity methods reported by the NGSP, can affect 
the HbA1c results using the Premier Hb9210 sys-
tem, which might be due to a lower glycation rate 
of HbF compared with that of HbA (7). The HbA1c 
concentrations can be misestimated with the 
Roche c501 instrument at a higher HbF level ( > 
5% in our study). However, there are no manufac-
turer claims of HbF interference. According to the 
NGSP, HbF levels > 10–15% can interfere with the 
Tina-quant Gen2 assay (7). Elevated HbF levels can 
occur under some pathological conditions such as 
beta-thalassemia, delta/beta-thalassemia, or a he-
reditary persistence of HbF (HPFH). The four instru-
ments would lead to inaccurate results using dif-
ferent concentrations of HbF; therefore, it is impor-
tant for laboratories to consider this fact in areas of 
a high prevalence of thalassemia or HPFH.
Over 1000 different Hb variants have been discov-
ered. Quantification of HbA1c in the presence of an 
Hb variant is an analytical challenge in the clinical 
laboratory. The most common Hb variants world-
wide in descending order of prevalence are HbS, 
HbE, HbC, and HbD. As the second most prevalent 
hemoglobinopathy worldwide, HbE is mostly 
found in the Far East and Southeast Asia; thus, it 
has been included in the present study (11). A 
good agreement of HbA1c concentrations was ob-
served between the Capillarys 2FP, Roche c501, 
and Premier Hb9210 analyzers; therefore, it was 
concluded that the HbA1c measurements on these 
three systems were not affected by the presence 
of the HbE variant, confirming the results reported 
previously (9,10,15,23-25,28). However, on the To-
soh G8 instrument, the presence of HbE induces 
an extra peak on the chromatogram, which is not 
reportable as shown previously (10,23). 
In summary, the four HbA1c methods commonly 
used with commercial analyzers showed a good 
comparability and reliability, although some inter-
ference may impede the results. 
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